2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET

Company Participants

Jenn Snyder - Senior Vice President, Corporate Affairs
Chip Baird - Chief Executive Officer
Vicki Eatwell - Chief Financial Officer
Anna Truppel-Hartmann - Chief Medical Officer

Conference Call Participants

Rabib Chaudhury - Leerink Partners
Matt Leskowitz - Goldman Sachs
Kelsey Goodwin - Guggenheim Securities
Morgan Gryga - Morgan Stanley
John Newman - Canaccord Genuity

Operator

Good day and thank you for standing by. Welcome to the 2seventy bio First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions]

Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Jenn Snyder with 2seventy bio. Please go ahead.

Jenn Snyder

Thank you, Shannon, and good morning, everyone. Thank you for joining us. This morning we issued a press release on our first quarter 2024 financial results. The press release can be found in the Investors and Media section of the company’s website at 2seventybio.com.

As a reminder, today’s discussion will include forward-looking statements related to 2seventy bio’s current plans and expectations, which are subject to certain risks and uncertainties. These forward-looking statements include statements regarding our strategic plans, timelines and expectations with respect to sales, efficacy and perceived therapeutic benefits of a Abecma, the timing and review of additional studies and regulatory applications for Abecma, and statements regarding our financial condition, expectations and future financial results, among others.

Actual results may differ materially due to various risks, uncertainties and other factors, including those described in the Risk Factors section of our most recent Form 10-K, quarterly reports and other SEC filings.

These forward-looking statements represent our views as of this call and should not be relied upon as representing our views as of any subsequent date. We are cautioned not to place any undue reliance on these forward-looking statements, and except as required by law, we undertake no obligation to update or revise any forward-looking statements.

On today’s call, we are joined by Chip Baird, Chief Executive Officer; and Vicki Eatwell, Chief Financial Officer. Anna Truppel-Hartmann, Chief Medical Officer, is also on the line for questions during the Q&A.

And now I will turn it over to Chip. Chip?

Chip Baird

Thank you, Jenn, and thank you all for joining this morning. Today we disclosed our first quarter 2024 financial results and recent business and operational updates. I’d like to walk through some of the business updates and then Vicki Eatwell, our Chief Financial Officer, will go into detail on our financials.